← FDA DRUG APPROVALS

FDA NDA · NDA216190

ONTRALFY

tizanidine hydrochloride

Sponsor: FIDELITY BIOPHARMA

APPLICATION
NDA216190
TYPE
NDA
ORIGINAL APPROVAL
2024-12-12
LATEST ACTION
2024-12-12
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ONTRALFY · ReferencePrescription
TIZANIDINE HYDROCHLORIDE EQ 2MG BASE/5ML · SOLUTION · ORAL

Approval history

2024-12-12Type 3 - New Dosage Form · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →